Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xingming Zhang

Showing results (101-110 of 121) with videos related to

Pageof 13
Sort By:
The Prostate|April 17, 2024
Predicting abiraterone efficacy in advanced prostate cancer: Insights from marker of proliferation Ki67Fengnian Zhao, Jinge Zhao, Xinyuan Wei, et al.
International Journal of Surgery (London, England)|October 25, 2024
Decade-long insights into transperineal prostate biopsy in a West China population: temporal trend, targeted and repeat biopsies, and pathological characterization: a comparative study - retrospective cohortJinge Zhao, Diming Cai, Yuntian Chen, et al.
Clinical Epigenetics|August 8, 2022
Integrated multi-omics analyses reveal that BCAM is associated with epigenetic modification and tumor microenvironment subtypes of clear cell renal cell carcinomaJunjie Zhao, Jiayu Liang, Yang Yang, et al.
BJU International|May 18, 2018
Novel nomograms for castration-resistant prostate cancer and survival outcome in patients with de novo bone metastatic prostate cancerJinge Zhao, Guangxi Sun, Banghua Liao, et al.
The Prostate|May 24, 2021
Dynamic multidisciplinary team discussions can improve the prognosis of metastatic castration-resistant prostate cancer patientsSha Zhu, Junru Chen, Yuchao Ni, et al.
The Prostate|August 26, 2021
The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancerZhipeng Wang, Sha Zhu, Jinge Zhao, et al.
The Prostate|July 12, 2019
AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapyJinge Zhao, Mengni Zhang, Jiandong Liu, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 8, 2025
Molecular Characterization of TFE3-Rearranged Renal Cell Carcinoma in Children and AdolescentsHaoyang Liu, Haolin Liu, Junru Chen, et al.
Molecular Cancer|June 26, 2024
Patients with ASPSCR1-TFE3 fusion achieve better response to ICI based combination therapy among TFE3-rearranged renal cell carcinomaJunjie Zhao, Yanfeng Tang, Xu Hu, et al.
BMC Medicine|July 21, 2022
Homologous recombination deficiency (HRD) score in aggressive prostatic adenocarcinoma with or without intraductal carcinoma of the prostate (IDC-P)Sha Zhu, Jinge Zhao, Ling Nie, et al.
Pageof 13

Showing results (101-110 of 121) with videos related to

Sort By:
Pageof 13
The Prostate|April 17, 2024
Predicting abiraterone efficacy in advanced prostate cancer: Insights from marker of proliferation Ki67Fengnian Zhao, Jinge Zhao, Xinyuan Wei, et al.
International Journal of Surgery (London, England)|October 25, 2024
Decade-long insights into transperineal prostate biopsy in a West China population: temporal trend, targeted and repeat biopsies, and pathological characterization: a comparative study - retrospective cohortJinge Zhao, Diming Cai, Yuntian Chen, et al.
Clinical Epigenetics|August 8, 2022
Integrated multi-omics analyses reveal that BCAM is associated with epigenetic modification and tumor microenvironment subtypes of clear cell renal cell carcinomaJunjie Zhao, Jiayu Liang, Yang Yang, et al.
BJU International|May 18, 2018
Novel nomograms for castration-resistant prostate cancer and survival outcome in patients with de novo bone metastatic prostate cancerJinge Zhao, Guangxi Sun, Banghua Liao, et al.
The Prostate|May 24, 2021
Dynamic multidisciplinary team discussions can improve the prognosis of metastatic castration-resistant prostate cancer patientsSha Zhu, Junru Chen, Yuchao Ni, et al.
The Prostate|August 26, 2021
The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancerZhipeng Wang, Sha Zhu, Jinge Zhao, et al.
The Prostate|July 12, 2019
AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapyJinge Zhao, Mengni Zhang, Jiandong Liu, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 8, 2025
Molecular Characterization of TFE3-Rearranged Renal Cell Carcinoma in Children and AdolescentsHaoyang Liu, Haolin Liu, Junru Chen, et al.
Molecular Cancer|June 26, 2024
Patients with ASPSCR1-TFE3 fusion achieve better response to ICI based combination therapy among TFE3-rearranged renal cell carcinomaJunjie Zhao, Yanfeng Tang, Xu Hu, et al.
BMC Medicine|July 21, 2022
Homologous recombination deficiency (HRD) score in aggressive prostatic adenocarcinoma with or without intraductal carcinoma of the prostate (IDC-P)Sha Zhu, Jinge Zhao, Ling Nie, et al.
Pageof 13